CClinicalTrials.gg
TerminatedNCT03289754Updated Oct 16, 2025Results posted

A Prospective Study to Evaluate the iTotal Knee and iPoly XE Tibial Inserts

An interventional study of iPoly XE tibial insert with ConforMIS iTotal KRS in Knee Osteoarthritis, sponsored by Restor3D. Terminated at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-16.

Sponsored by Restor3D · Not applicable, Interventional, and Basic science

Why this study was terminated
Decision of investigational team
Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is designed to evaluate the clinical outcomes of subjects who have recently undergone surgery with the iTotal® Cruciate Retaining (CR) Total Knee Replacement System (KRS) who have also had iPoly XE Tibial Inserts implanted.

Read the detailed description

The study is prospective and single-center. Subjects will be implanted with an iTotal® CR Knee Replacement System in conjunction with an iPoly XE insert. The study will include a minimum of 50 subjects and a maximum of 60 subjects at a single center. The study site will be located in Germany. The study subjects will be followed for 10 years post implant.

02

Conditions studied

  • Knee Osteoarthritis

Keywords

  • knee implant
  • osteoarthritis
  • patient-specific
  • knee osteoarthritis
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Clinical condition included in the approved Indications For Use for the iTotal® CR
  2. Osteoarthritis, as confirmed by the investigator's assessment of disease status at screening visit that warrants a TKR procedure. Disease status is assessed by Clinical and Radiographic assessment.
  3. Willingness to participate in the clinical study, to give informed consent, and to attend all follow-up visits
  4. > 18 years of age

Exclusion criteria

Exclusion Criteria:

  1. Simultaneous bilateral procedure required
  2. BMI > 40
  3. Active malignancy (defined as a history of any invasive malignancy - except non-melanoma skin cancer), unless patient has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years
  4. Poorly controlled diabetes
  5. Neuromuscular conditions which prevent patient from participating in study activities
  6. Active local or systemic infection
  7. Immunocompromised
  8. Fibromyalgia or other general body pain related condition
  9. Rheumatoid arthritis or other forms of inflammatory joint disease
  10. Loss of bone or musculature, osteonecrosis, neuromuscular or vascular compromise in the area of the joint to be operated on, to an extent that the procedure is unjustified
  11. Diagnosed with or receiving treatment for Osteoporosis
  12. Other physical disability affecting the hips, spine, or contralateral knee
  13. Severe instability due to advanced loss of osteochondral structure
  14. Prior arthroplasty of the affected knee, including High Tibial Osteotomy (HTO)
  15. Compromised PCL or collateral ligament
  16. Severe fixed valgus or varus deformity of >15º
  17. Extensor lag > 15º
  18. Fixed flexion contracture ≥ 15º
  19. Unwilling or unable to comply with study requirements
  20. Participation in another clinical study which would confound results
  21. Allergy to any of the implant materials
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    ConforMIS iTotal Knee with iPoly Insert

    The tibial insert being utilized in this study will be a highly-crosslinked, Vitamin-E enriched UHMWPE (iPoly XE) instead of traditional tibial inserts.

    Device: iPoly XE tibial insert with ConforMIS iTotal KRS

Interventions

  • DeviceiPoly XE tibial insert with ConforMIS iTotal KRS

    The implants are constructed to conform to the surface of the patient's femoral condyle and proximal tibia, replacing the damaged cartilage with a smooth articulating surface. The femoral component and tibial tray are manufactured from cobalt chromium molybdenum alloy. The tibial insert and patellar component are manufactured from ultra-high molecular weight polyethylene.

05

What researchers measure

Primary outcomes

  1. Incidence of Device-related Complications

    Adverse events were categorized as "Device Probably Related", "Device Possibly Related", Device All Related", or "Device Not Related" by the care team for all adverse events (as per the definitions of adverse events on clinicaltrials.gov). Outcome metrics are given in the form of "Events per Patient" which was calculated by dividing the number of adverse in each category by the number of baseline patients.

    Time frame: 1 year

  2. Incidence of Procedure-Related Complications

    Adverse events were categorized as "Procedure Probably Related", "Procedure Possibly Related", Procedure All Related", or "Procedure Not Related" by the care team for all adverse events (as per the definitions of adverse events on clinicaltrials.gov). Outcome metrics are given in the form of "Events per Patient" which was calculated by dividing the number of adverse in each category by the number of baseline patients.

    Time frame: 1 year

06

Results

Posted Oct 16, 2025

Participant flow

Participant flow — Overall Study
MilestoneConforMIS iTotal Knee With iPoly Insert
Started52
Completed49
Not completed3
Withdrew: Screen failure or failure to meet follow-up3

Outcome measures

PrimaryIncidence of Device-related Complications

Adverse events were categorized as "Device Probably Related", "Device Possibly Related", Device All Related", or "Device Not Related" by the care team for all adverse events (as per the definitions of adverse events on clinicaltrials.gov). Outcome metrics are given in the form of "Events per Patient" which was calculated by dividing the number of adverse in each category by the number of baseline patients.

Time frame:
1 year
Reported as:
Number · Events per Patient
Incidence of Device-related Complications
Events per Patient"Device Probably Related" Adverse Event"Device Possibly Related" Adverse Event"Device All Related" Adverse Event"Device Not Related" Adverse Event
Incidence of Device-related Complications0.020.310.330.39
PrimaryIncidence of Procedure-Related Complications

Adverse events were categorized as "Procedure Probably Related", "Procedure Possibly Related", Procedure All Related", or "Procedure Not Related" by the care team for all adverse events (as per the definitions of adverse events on clinicaltrials.gov). Outcome metrics are given in the form of "Events per Patient" which was calculated by dividing the number of adverse in each category by the number of baseline patients.

Time frame:
1 year
Reported as:
Number · Events per Patient
Incidence of Procedure-Related Complications
Events per Patient"Procedure Probably Related" Adverse Event"Procedure Possibly Related" Adverse Event"Procedure All Related" Adverse Event"Procedure Not Related" Adverse Event
Incidence of Procedure-Related Complications0.10.140.240.47

Adverse events

Collected over Adverse Events were collected from surgery date until 1 year post-operation.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ConforMIS iTotal Knee With iPoly Insert1/49 (2%)15/49 (30.6%)12/49 (24.5%)
Most frequent serious events
Most frequent serious events
EventConforMIS iTotal Knee With iPoly Insert
HospitalizationGeneral disorders7/49
Medical InterventionGeneral disorders5/49
Life-threateningGeneral disorders2/49
DeathCongenital, familial and genetic disorders1/49
OtherGeneral disorders1/49
DisabilityGeneral disorders0/49
Most frequent other events
Most frequent other events
EventConforMIS iTotal Knee With iPoly Insert
Pain/Stiffness ComplicationsGeneral disorders6/49
Infection ComplicationsInfections and infestations3/49
Wound InfectionSkin and subcutaneous tissue disorders2/49
Thrombotic ComplicationsVascular disorders1/49

Baseline characteristics

Study terminated early.

Age, Continuous
Age, Continuous(years)ConforMIS iTotal Knee With iPoly Insert
Mean66.27 (45 to 87)
Sex: Female, Male
Sex: Female, Male(Participants)ConforMIS iTotal Knee With iPoly Insert
Female30
Male18
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)ConforMIS iTotal Knee With iPoly Insert
Region of Enrollment
Region of Enrollment(participants)ConforMIS iTotal Knee With iPoly Insert
Germany49
07

Study locations

1 site
  • University Medical Center of Johannes Gutenberg-University Mainz
    Mainz, Germany
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Jun 30, 2016

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03289754
Lead sponsor
Restor3D
Responsible party
Sponsor
First posted
Sep 21, 2017
Start date
Jan 24, 2018
Primary completion
Jun 9, 2022
Completion
Jun 9, 2022
Results posted
Oct 16, 2025
Last update
Oct 16, 2025

Study contacts

Philipp Drees
principal investigator · University- Mainz

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion